Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Idiopathic Focal Segmental Glomerulosclerosis”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Testing effectiveness (Phase 2)Study completedNCT03422510
What this trial is testing

FIRSTx - A Study of Oral CXA-10 in Primary Focal Segmental Glomerulosclerosis (FSGS)

Who this might be right for
Primary Focal Segmental Glomerulosclerosis
Complexa, Inc. 33
Large-scale testing (Phase 3)Study completedNCT01268033
What this trial is testing

Efficacy of Rituximab For the Treatment of Calcineurin Inhibitors Dependent Nephrotic Syndrome During Childhood

Who this might be right for
Childhood Idiopathic Nephrotic Syndrome
University Hospital, Limoges 26
Testing effectiveness (Phase 2)Looking for participantsNCT06466135
What this trial is testing

Study of WAL0921 in Patients With Glomerular Kidney Diseases

Who this might be right for
Diabetic NephropathiesPrimary Focal Segmental GlomerulosclerosisMinimal Change Disease+2 more
Walden Biosciences 96
Large-scale testing (Phase 3)Looking for participantsNCT07220083
What this trial is testing

Find Out if BI 764198 Helps Adults and Adolescents With a Kidney Condition Called Focal Segmental Glomerulosclerosis (FSGS)

Who this might be right for
Focal Segmental Glomerulosclerosis
Boehringer Ingelheim 286
Testing effectiveness (Phase 2)Study completedNCT01613118
What this trial is testing

Randomized, Double-Blind, Safety and Efficacy Study of RE-021 (Sparsentan) in Focal Segmental Glomerulosclerosis

Who this might be right for
Focal Segmental Glomerulosclerosis
Travere Therapeutics, Inc. 109
Not applicableLooking for participantsNCT07516964
What this trial is testing

SLIT ABS: Study on Patients With Autoimmune Podocytopathy

Who this might be right for
Nephrotic Syndrome With Edema (Diagnosis)Minimal Change Nephrotic SyndromeFocal Segmental Glomerulosclerosis (FSGS)+1 more
Meyer Children's Hospital IRCCS 50
Early research (Phase 1)WithdrawnNCT00816504
What this trial is testing

Effect of Galactose on Permeblity Factor in Patients With FSGS and CKD Stage 5

Who this might be right for
Focal Segmental Glomerulosclerosis
Northwell Health
Not applicableStudy completedNCT00801463
What this trial is testing

Prednisone Plus Tripterygium Wilfordii Treatment of Adult Patients With Idiopathic Focal Segmental Glomerulosclerosis

Who this might be right for
ProteinuriaFocal Segmental Glomerulosclerosis
Nanjing University School of Medicine 67
Large-scale testing (Phase 3)Study completedNCT00404833
What this trial is testing

Mycophenolate Mofetil in Membranous Nephropathy and Focal Segmental

Who this might be right for
Glomerulonephritis, MembranousGlomerulosclerosis, Focal
Hospital Authority, Hong Kong 16
Post-approval studies (Phase 4)Study completedNCT02633046
What this trial is testing

Acthar for Treatment-Resistant or Treatment-Intolerant Proteinuria

Who this might be right for
Idiopathic Focal Segmental Glomerulosclerosis
Mallinckrodt ARD LLC 63
Not applicableLooking for participantsNCT04065438
What this trial is testing

Post Approval Study for Treatment of Drug-resistant Adult and Pediatric Primary FSGS Using the LIPOSORBER® LA-15 System

Who this might be right for
Focal Segmental Glomerulosclerosis
Kaneka Medical America LLC 35
Testing effectiveness (Phase 2)Looking for participantsNCT06500702
What this trial is testing

Evaluate the Efficacy and Safety of Frexalimab, Brivekimig, or Rilzabrutinib in Participants Aged 16 to 75 Years With Primary Focal Segmental Glomerulosclerosis or Minimal Change Disease

Who this might be right for
Focal Segmental GlomerulosclerosisGlomerulonephritis Minimal Lesion
Sanofi 84
Not applicableLooking for participantsNCT02235857
What this trial is testing

Post Approval Study of Liposorber LA-15 System for the Treatment of Focal Segmental Glomerulosclerosis in Children

Who this might be right for
Focal Segmental Glomerulosclerosis
Kaneka Medical America LLC 35
Testing effectiveness (Phase 2)WithdrawnNCT05599815
What this trial is testing

Part 1 - A Clinical Trial in Patients With Frequently Relapsing and Steroid-Dependent Nephrotic Syndrome

Who this might be right for
Nephrotic Syndrome
Aldeyra Therapeutics, Inc.
Not applicableWithdrawnNCT00302536
What this trial is testing

Tacrolimus Treatment of Patients With Idiopathic Focal Segmental Glomerulosclerosis

Who this might be right for
Focal Glomerulosclerosis
Nanjing University School of Medicine
Early research (Phase 1)Ended earlyNCT00816478
What this trial is testing

Effect of Oral Galactose on Focal Segmental Glomerulosclerosis (FSGS) Permeability Factor

Who this might be right for
Focal Segmental Glomerulosclerosis
Northwell Health 15
Not applicableLooking for participantsNCT06334692
What this trial is testing

Autoantibodies Against-nephrin in Idiopathic Nephrotic Syndrome

Who this might be right for
Nephrotic Syndrome
Mario Negri Institute for Pharmacological Research 100
Not applicableLooking for participantsNCT03949972
What this trial is testing

The FOrMe Registry (The German Focal Segmental Glomerulosclerosis and Minimal Change Disease Registry)

Who this might be right for
Glomerulosclerosis, Focal SegmentalMinimal Change DiseaseIdiopathic Nephrotic Syndrome
Prof. Dr. Paul Brinkkoetter 500
Not applicableStudy completedNCT04369183
What this trial is testing

Rituximab for Refractory or Relapsed Focal Segmental Glomerulosclerosis or Minimal Change Disease

Who this might be right for
Focal Segmental GlomerulosclerosisMinimal Change Disease
Istanbul University 25
Early research (Phase 1)Study completedNCT00464321
What this trial is testing

Safety Study of GC1008 in Patients With Focal Segmental Glomerulosclerosis (FSGS) of Single Doses of GC1008 in Patients With Treatment Resistant Idiopathic FSGS

Who this might be right for
Focal Segmental Glomerulosclerosis
Genzyme, a Sanofi Company 16
Next Page